Search clinical trials for: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

Total 267 results

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Platinum-resistant Ovarian Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor

Advanced Solid Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Peripheral T Cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Advanced Gastric Carcinoma

China
Institute of Hematology & Blood Diseases Hospital...
CSPC Ouyi Pharmaceutical Co., Ltd.

Active, not recruiting

GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Non Hodgkin Lymphoma

China
Hui Zeng
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Unresectable or Metastatic Bone and Soft Tissue Sarcoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Breast Cancer

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Withdrawn

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

Recurrent/Refractory Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell and NK/T-cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer

Advanced Recurrent or Metastatic Breast Cancer

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Recruiting

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Relapsed or Refractory Multiple Myeloma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC

Advanced Hepatocellular Carcinoma
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Recurrent Metastatic Nasopharyngeal Carcinoma
Ayana Pharma Ltd.,
Lambda Therapeutic Research Ltd.

Completed

A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

Ovarian Cancer Recurrent

India
Children's Hospital of Soochow University

Recruiting

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML (GMCAII)

Acute Myeloid Leukemia | AML, Childhood

China
InxMed (Shanghai) Co., Ltd.

Active, not recruiting

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Locally Advanced or Metastatic Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Extranodal NK/T-cell Lymphoma, Nasal Type

China
Second Affiliated Hospital of Soochow University
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
European Organisation for Research and Treatment...

Completed

Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer

Ovarian Cancer

France, Spain, United Kingdom, Belgium, Israel, Switzerland, Italy
Luye Pharma Group Ltd.

Completed

Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors

Advanced Solid Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor

Advanced Malignant Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Mitoxantrone Hydrochloride Liposome Injection

Malignant Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of Mitoxantrone Hydrochloride Liposome Infusion

Non-Hodgkin's Lymphoma

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

Relapsed Cutaneous T Cell Lymphom

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs

Relapsed DLBCL and PT/NKCLs

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection

Neoplasms
Astex Pharmaceuticals, Inc.

Unknown

Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer

Colorectal Cancer

United States
MD Stem Cells

Unknown

Stem Cell Ophthalmology Treatment Study (SCOTS)

Glaucoma | Macular Degeneration | Retinal Disease | Hereditary Retinal Dystrophy | Optic Nerve Disease

United States
Wuhan Union Hospital, China
CSPC Pharmaceutical Group Limited

Recruiting

Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies

B-cell Acute Lymphoblastic Leukemia | B-cell Lymphoma Refractory

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

Advanced Solid Tumor
Fudan University

Recruiting

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Advanced Malignant Tumors

China
Luye Pharma Group Ltd.

Completed

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Ovarian Epithelial Cancer Recurrent

India
Tianjin Medical University Second Hospital
CSPC Pharmaceutical Group Limited

Unknown

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Muscle Invasive Bladder Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Bioequivalence

China
Cancer Institute and Hospital, Chinese Academy...
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Breast Cancer

China
Telik

Completed

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Ovarian Neoplasms

United States, Czech Republic, South Africa, Argentina, Belgium, Spain, Brazil, Chile, Germany, Hungary, Ireland, Netherlands, United Kingdom
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

3-Tesla MRI Response to TACE in HCC (Liver Cancer)

Advanced Adult Primary Liver Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | Stage A Adult Primary Liver Cancer (BCLC) | Stage B Adult Primary Liver Cancer (BCLC)

United States
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Acute Myeloid Leukemia
Fudan University

Not yet recruiting

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Small Cell Lung Cancer Recurrent

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Search clinical trials for: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations